Comparative Pharmacology
Head-to-head clinical analysis: SILODOSIN versus UROXATRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SILODOSIN versus UROXATRAL.
SILODOSIN vs UROXATRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Silodosin is a highly selective antagonist of alpha-1A adrenergic receptors located primarily in the prostate, bladder base, and proximal urethra. Blockade of these receptors relaxes smooth muscle in these tissues, reducing urinary outflow resistance and improving symptoms of benign prostatic hyperplasia (BPH). It has minimal affinity for alpha-1B receptors, thereby reducing the risk of orthostatic hypotension compared to non-selective alpha blockers.
Selective antagonist of postsynaptic alpha1A-adrenoceptors in the prostate, bladder base, and prostatic urethra, leading to relaxation of smooth muscle and improved urinary flow.
8 mg orally once daily with a meal.
10 mg orally once daily, immediately after the same meal each day.
None Documented
None Documented
Clinical Note
moderateSilodosin + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Silodosin."
Clinical Note
moderateSilodosin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Silodosin."
Clinical Note
moderateSilodosin + Tranilast
"Silodosin may increase the hypotensive activities of Tranilast."
Clinical Note
moderateSilodosin + Prednisone
Terminal half-life: 11-13 hours; allows once-daily dosing; prolongation in severe renal impairment
The terminal elimination half-life is approximately 5 to 9 hours in healthy young subjects, and 6 to 10 hours in elderly patients. This supports once-daily dosing, with steady state achieved after 3-5 days.
Renal (33.5% as unchanged drug, 64.3% as metabolites); fecal (<5%)
After oral administration, approximately 11% of the dose is excreted unchanged in urine, while 49% is excreted as metabolites in urine and 22% in feces. Overall, renal elimination accounts for about 60% of total clearance.
Category A/B
Category C
Alpha-1 Blocker
Alpha-1 Blocker
"The serum concentration of Prednisone can be increased when it is combined with Silodosin."